## **Shmuel Yaccoby**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8054000/publications.pdf Version: 2024-02-01



| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Research, 2022, 32, 1343-1354.  | 5.5 | 8         |
| 2  | PHF19 inhibition as a therapeutic target in multiple myeloma. Current Research in Translational<br>Medicine, 2021, 69, 103290.  | 1.8 | 5         |
| 3  | Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC </i> and <i>PVT1 </i> in multiple myeloma. Haematologica, 2020, 105, 1055-1066.                         | 3.5 | 42        |
| 4  | CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction. Blood, 2020, 136, 21-21.   | 1.4 | 0         |
| 5  | Mesenchymal stem cells gene signature in highâ€risk myeloma bone marrow linked to suppression of<br>distinct IGFBP2â€expressing small adipocytes. British Journal of Haematology, 2019, 184, 578-593. | 2.5 | 18        |
| 6  | The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple<br>Myeloma. Clinical Cancer Research, 2018, 24, 2913-2919.  | 7.0 | 30        |
| 7  | Two States of Myeloma Stem Cells. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 38-43.   | 0.4 | 12        |
| 8  | Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of<br>Distinct IGFBP2-Expressing Small Adipocytes. Blood, 2018, 132, 4448-4448.                          | 1.4 | 0         |
| 9  | Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk<br>Microenvironment Via Augmented Bioavailability of Growth Factors. Blood, 2018, 132, 1929-1929.         | 1.4 | 0         |
| 10 | Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients<br>With Multiple Myeloma. Journal of Bone and Mineral Research, 2017, 32, 1261-1266.           | 2.8 | 9         |
| 11 | The prognostic value of the depth of response in multiple myeloma depends on the time of assessment,<br>risk status and molecular subtype. Haematologica, 2017, 102, e313-e316.                       | 3.5 | 26        |
| 12 | The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma. Haematologica, 2017, 102, e364-e367.                           | 3.5 | 57        |
| 13 | Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to<br>Fractionated Melphalan Transplants. Clinical Cancer Research, 2017, 23, 2665-2672.                          | 7.0 | 13        |
| 14 | Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?.<br>Immunotherapy, 2016, 8, 367-384.   | 2.0 | 6         |
| 15 | A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes<br>Multiple Myeloma Cells to PARP Inhibition. Molecular Cancer Therapeutics, 2016, 15, 241-250.      | 4.1 | 58        |
| 16 | Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High<br>Risk Myeloma. Blood, 2016, 128, 2065-2065.   | 1.4 | 1         |
| 17 | Myeloma Exosomes Prime the Microenvironment to Support Survival and Growth of Myeloma Cells.<br>Blood, 2016, 128, 2067-2067.  | 1.4 | 2         |
| 18 | Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk<br>Stratification and Targeted Treatment. Blood, 2016, 128, 3278-3278.                         | 1.4 | 2         |

SHMUEL YACCOBY

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the<br>Growth of Myeloma Cells from Low-Risk Patients. Blood, 2016, 128, 3304-3304.  | 1.4 | 3         |
| 20 | The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. Blood, 2016, 128, 4431-4431.  | 1.4 | 8         |
| 21 | The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States.<br>Blood, 2016, 128, 4438-4438.   | 1.4 | 0         |
| 22 | Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma<br>(SWOG S0120). Haematologica, 2015, 100, 1214-1221.   | 3.5 | 44        |
| 23 | Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer, 2015, 15, 864.  | 2.6 | 11        |
| 24 | A peptide nucleic acid targeting nuclear <i>RAD51</i> sensitizes multiple myeloma cells to melphalan treatment. Cancer Biology and Therapy, 2015, 16, 976-986.  | 3.4 | 14        |
| 25 | The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. Blood, 2015, 126, 1806-1806.  | 1.4 | 2         |
| 26 | Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines. Blood, 2015, 126, 1808-1808.   | 1.4 | 2         |
| 27 | Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). Blood, 2015, 126, 1843-1843.   | 1.4 | 1         |
| 28 | High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal<br>Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. Blood,<br>2015, 126, 20-20. | 1.4 | 7         |
| 29 | The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM. Blood, 2015, 126, 372-372.   | 1.4 | 1         |
| 30 | Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy. Blood, 2015, 126, 1820-1820.   | 1.4 | 1         |
| 31 | Molecular Subtyping and Risk Stratification for the Classification of Myeloma. Blood, 2015, 126, 4173-4173.   | 1.4 | Ο         |
| 32 | Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma<br>(RRMM). Blood, 2015, 126, 5395-5395.  | 1.4 | 0         |
| 33 | CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood, 2014, 124, 2051-2060.   | 1.4 | 26        |
| 34 | Curing Multiple Myeloma (MM) with Total Therapy (TT). Blood, 2014, 124, 195-195.  | 1.4 | 3         |
| 35 | Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in<br>Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. Blood, 2014, 124, 3409-3409.                   | 1.4 | 5         |
| 36 | A Peptide Nucleic Acid Targeting Nuclear Rad51 Sensitizes Myeloma Cells to Melphalan Chemotoxicity<br>Both in Vitro and in Vivo. Blood, 2014, 124, 3529-3529.   | 1.4 | 5         |

Shmuel Yaccoby

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is<br>Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1.<br>Blood, 2014, 124, 3403-3403. | 1.4 | 0         |
| 38 | Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Blood, 2014, 124, 479-479.   | 1.4 | 5         |
| 39 | Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm<br>Requiring Therapy in S0120 Patients Treated at Mirt. Blood, 2014, 124, 2078-2078.  | 1.4 | 0         |
| 40 | ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis.<br>Blood, 2014, 124, 2102-2102.   | 1.4 | 1         |
| 41 | Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early<br>Development of MDS Cytogenetic Abnormalities and Poor Overall Survival. Blood, 2014, 124, 2012-2012.                          | 1.4 | 0         |
| 42 | NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.<br>Experimental Hematology, 2013, 41, 547-557.e2.   | 0.4 | 39        |
| 43 | Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. American<br>Journal of Hematology, 2013, 88, 463-471.  | 4.1 | 53        |
| 44 | Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica, 2013, 98, 71-78.   | 3.5 | 80        |
| 45 | Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in<br>Multiple Myeloma. PLoS ONE, 2013, 8, e74191.  | 2.5 | 39        |
| 46 | MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma. Blood, 2013, 122, 281-281.  | 1.4 | 1         |
| 47 | Healthy Donor Whole Bone Marrow Cells Preconditioned With Myeloma Patient Serum Support<br>Long-Term Survival Of Primary Myeloma and Reveal Altered Microenvironmental Pathways. Blood,<br>2013, 122, 3118-3118.             | 1.4 | 0         |
| 48 | Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their<br>Growth But Suppresses Metastasis. Blood, 2013, 122, 4432-4432.  | 1.4 | 0         |
| 49 | Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma<br>Activity In a Supportive Microenvironment In Vivo and In Vitro. Blood, 2013, 122, 1926-1926.                                | 1.4 | 1         |
| 50 | Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.<br>Haematologica, 2012, 97, 1348-1356.  | 3.5 | 97        |
| 51 | Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. Journal of Bone and Mineral Research, 2012, 27, 1635-1648.   | 2.8 | 34        |
| 52 | A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica, 2011, 96, 333-336.                             | 3.5 | 52        |
| 53 | Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress<br>Growth of Multiple Myeloma in Bone. Stem Cells, 2011, 29, 263-273.  | 3.2 | 71        |
| 54 | Secreted Frizzled-Related Protein-3 (sFRP3) Is Produced by Myeloma Cells and Augments Wnt3a-Induced Differentiation of Mesenchymal Stem Cells and OPG Production in Osteoblasts. Blood, 2011, 118, 808-808.                  | 1.4 | 1         |

Shmuel Yaccoby

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Inducible Heme Oxygenase 1 (HMOX1) Promotes Osteoblastogenesis, and Inhibits Osteoclastogenesis and Myeloma-Induced Bone Disease. Blood, 2011, 118, 627-627.   | 1.4 | 3         |
| 56 | Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and<br>Osteoclasts, and Promote Myeloma Growth and Bone Disease,. Blood, 2011, 118, 3941-3941.   | 1.4 | 0         |
| 57 | Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis. Blood, 2011, 118, 884-884.  | 1.4 | 6         |
| 58 | Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma. Blood, 2011, 118, 2918-2918.   | 1.4 | 8         |
| 59 | Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis<br>in multiple myeloma. Blood, 2010, 115, 61-70.   | 1.4 | 79        |
| 60 | Advances in the understanding of myeloma bone disease and tumour growth. British Journal of Haematology, 2010, 149, 311-321.   | 2.5 | 82        |
| 61 | Osteoblastogenesis and tumor growth in myeloma. Leukemia and Lymphoma, 2010, 51, 213-220.  | 1.3 | 48        |
| 62 | The role of the proteasome in bone formation and osteoclastogenesis. IBMS BoneKEy, 2010, 7, 147-155.   | 0.0 | 2         |
| 63 | Repression of Multiple Myeloma Growth and Preservation of Bone with Combined Radiotherapy and Anti-angiogenic Agent. Radiation Research, 2010, 173, 809-817.   | 1.5 | 13        |
| 64 | Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and<br>Molecular Profiling of Whole Myelomatous Bone. PLoS ONE, 2010, 5, e15233.   | 2.5 | 38        |
| 65 | Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. British Journal of Haematology, 2009, 145, 775-787.   | 2.5 | 25        |
| 66 | Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Letters, 2009, 284, 175-181.   | 7.2 | 17        |
| 67 | The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. American Journal of Hematology, 2009, 84, 6-14.   | 4.1 | 132       |
| 68 | The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood, 2009, 114, 1803-1812.   | 1.4 | 94        |
| 69 | Role of decorin in the antimyeloma effects of osteoblasts. Blood, 2008, 112, 159-168.  | 1.4 | 102       |
| 70 | Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood, 2008, 112, 374-382.  | 1.4 | 87        |
| 71 | Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome<br>Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing<br>Multi-Agent Chemotherapy. Blood, 2008, 112, 733-733. | 1.4 | 10        |
| 72 | Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. Journal of<br>Clinical Oncology, 2007, 25, 1121-1128.  | 1.6 | 369       |

SHMUEL YACCOBY

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 2007, 109, 2106-2111.  | 1.4  | 414       |
| 74 | The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood, 2007, 109, 4470-4477.  | 1.4  | 80        |
| 75 | Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. American Journal of Hematology, 2007, 82, 831-833.                     | 4.1  | 34        |
| 76 | Establishment and exploitation of hyperdiploid and nonâ€hyperdiploid human myeloma cell lines. British<br>Journal of Haematology, 2007, 138, 802-811.   | 2.5  | 27        |
| 77 | Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative<br>Interventions for Myeloma and Its Associated Bone Disease Blood, 2007, 110, 548-548.             | 1.4  | 2         |
| 78 | Inhibitors of Fibroblast Activation Protein (FAP) Inhibit Primary Myeloma Growth and<br>Osteoclastogenesis Ex Vivo and In Vivo Blood, 2007, 110, 813-813.   | 1.4  | 1         |
| 79 | Small Leucine-Rich Proteoglycans (SLRPs) Are Involved in the Anti-Myeloma Response of Osteoblasts<br>Blood, 2007, 110, 815-815.   | 1.4  | 8         |
| 80 | The molecular classification of multiple myeloma. Blood, 2006, 108, 2020-2028.  | 1.4  | 997       |
| 81 | Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma. Clinical Lymphoma and<br>Myeloma, 2006, 7, 109-114.   | 1.4  | 46        |
| 82 | Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. British Journal of Haematology, 2006, 133, 83-92.  | 2.5  | 51        |
| 83 | Targeting β2-microglobulin for induction of tumor apoptosis in human hematological malignancies.<br>Cancer Cell, 2006, 10, 295-307.   | 16.8 | 92        |
| 84 | Fenretinide (4HPR) Inhibits Growth of Myeloma Cells in Their Microenvironment and Is a Potent<br>Inhibitor of Angiogenesis and Osteoclastogenesis Blood, 2006, 108, 3480-3480.                        | 1.4  | 0         |
| 85 | JNK Regulates DKK1 Expression in Multiple Myeloma Cells Blood, 2006, 108, 3411-3411.  | 1.4  | 0         |
| 86 | Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica, 2006, 91, 192-9.                                     | 3.5  | 127       |
| 87 | Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.<br>British Journal of Haematology, 2005, 131, 71-73.   | 2.5  | 180       |
| 88 | The Phenotypic Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature,<br>Resilient, and Apoptosis-Resistant Phenotype. Clinical Cancer Research, 2005, 11, 7599-7606. | 7.0  | 78        |
| 89 | The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity Blood, 2005, 106, 510-510.   | 1.4  | 2         |
| 90 | Anti-Myeloma Response to Bortezomib Is Associated with Increased Osteoblast Activity and Bone Formation in Primary Myelomatous SCID-rab Mice Blood, 2005, 106, 3450-3450.                             | 1.4  | 1         |

SHMUEL YACCOBY

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 91 | Cancer and the Microenvironment. Cancer Research, 2004, 64, 2016-2023.   | 0.9 | 175       |
| 92 | Consequences of interactions between the bone marrow stroma and myeloma. The Hematology Journal, 2003, 4, 310-314.   | 1.4 | 32        |
| 93 | Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood, 2002, 100, 4162-4168.   | 1.4 | 63        |
| 94 | Myeloma interacts with the bone marrow microenvironment â€`to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology, 2002, 116, 278-290. | 2.5 | 271       |
| 95 | Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood, 2000, 96, 2528-2536.                     | 1.4 | 103       |
| 96 | The Proliferative Potential of Myeloma Plasma Cells Manifest in the SCID-hu Host. Blood, 1999, 94, 3576-3582.  | 1.4 | 155       |
| 97 | Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations. Blood, 1998, 92, 2908-2913.                         | 1.4 | 238       |
| 98 | Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of<br>Myeloma and Its Manifestations. Blood, 1998, 92, 2908-2913.                      | 1.4 | 6         |